Reduced intensity conditioning and prophylactic DLI can cure patients with high-risk acute leukaemias if complete donor chimerism can be achieved

Bone Marrow Transplantation

Volumn 31, Issue 5, 2003, Pages 339-345

  Massenkeil, G ^a   Nagy, M ^b   Lawang, M ^b   Rosen, O ^a   Genvresse, I ^a   Geserick, G ^b   Dorken B ^a   Arnold, R ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Acute leukaemia; Donor lymphocyte infusion (DLI); Mixed chimerism; Nonmyeloablative stem cell transplantation (NST); STR analysis

Indexed keywords

BUSULFAN; CYCLOSPORIN A; FLUDARABINE; GENOMIC DNA; IMMUNOSUPPRESSIVE AGENT; MOLECULAR MARKER; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; THYMOCYTE ANTIBODY;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ADVANCED CANCER; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CHIMERA; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DONOR; FEMALE; FOLLOW UP; GENETIC ANALYSIS; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HLA MATCHING; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA REMISSION; LYMPHOCYTE TRANSFUSION; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECIPIENT; RECURRENCE RISK; SEPSIS; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TANDEM REPEAT;

ADULT; AGED; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOCYTIC, ACUTE; LYMPHOCYTE TRANSFUSION; MALE; MIDDLE AGED; TANDEM REPEAT SEQUENCES; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING;

EID: 0037355746     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703859     Document Type: Article

References (35)

1. Stewart FM, Zhong S, Wuu J et al. Lymphohematopoietic engraftment in minimally myeloablated hosts. Blood 1998; 91: 3681-3687.
2. Storb R, Yu C, Barnett T et al. Stable mixed hematopoietic chimerism in dog leucocyte antigen-identical littermate dogs given lymph node irradiation before and pharmacologic immunosuppression after marrow transplantation. Blood 1999; 94: 1131-1136.
3. Davies S, Kollman C, Anasetti C et al. Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the national marrow donor program. Blood 2000; 96: 4096-4102.
4. Slavin S, Nagler A, Naparstek E et al. Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non malignant hematological diseases. Blood 1998; 91: 756-763.
5. Khouri IF, Keating M, Korbling M et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817-2824.
6. Childs R, Clave E, Contentin N et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999; 94: 3234-3241.
7. Giralt S, Thall PF, Khouri I et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001; 97: 631-637.
8. McSweeney PA, Niederwieser D, Shizuru JA et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-3400.
9. Bornhauser M, Thiede C, Platzbecker U et al. Dose-reduced conditioning and allogencic hematopoietic stem cell transplantation from unrelated donors in 42 patients. Clin Cancer Res 2001; 7: 2254-2262.
10. Thiede C, Florek M, Bornhauser M et al. Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection. Bone Marrow Transplant 1999; 23: 1055-1060.
11. Lion T, Daxberger H, Dubovsky J et al. Analysis of chimerism within specific leucocyte subsets for detection of residual or recurrent leukemia in pediatric patients after allogeneic stem cell transplantation. Leukemia 2001; 15: 307-310.
12. Storb R, Yu C, Wagner JL et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997; 89: 3048-3054.
13. Huss R, Deeg HJ, Gooley T et al. Effect of mixed chimerism on graft-versus-host disease, disease recurrence and survival after HLA-identical marrow transplantation for aplastic anemia or chronic myelogenous leukemia. Bone Marrow Transplant 1996; 18: 767-776.
14. Bader P, Beck J, Frey A et al. Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT. Bone Marrow Transplant 1998; 21: 487-495.
15. Choi SJ, Lee KH, Lee JH et al. Prognostic value of hematopoietic chimerism in patients with acute leukemia after allogeneic bone marrow transplantation: a prospective study. Bone Marrow Transplant 2000; 26: 327-332.
16. Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86: 2041-2050.
17. Porter DL, Roth MS, Lee SJ et al. Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation. Bone Marrow Transplant 1996; 18: 975-980.
18. Collins Jr RH, Goldstein S, Giralt S et al. Donor leucocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant 2000; 26: 511-516.
19. Bader P, Klingebiel T, Schaudt A et al. Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children. Leukemia 1999; 13: 2079-2086.
20. Blin N, Stafford DW. A general method for isolation of high molecular weight DNA from eukaryotes. Nucleic Acids Res 1976; 3: 2303-2308.
21. Li H, Schmidt L, Wei MH et al. Three tetranucleotide polymorphisms for loci: D3S1352; D3S1358; D3S1359. Hum Mol Genet 1993; 2: 1327.
22. Kimpton C, Walton A, Gill P. A further tetranucleotide repeat polymorphism in the vWF gene. Hum Mol Genet 1992; 1: 287.
23. Mills KA, Even D, Murray JC. Tetranucleotide repeat polymorphism at the human alpha fibrinogen locus (FGA). Hum Mol Genet 1992; 1: 779.
24. Oldroyd NJ, Urquhart AJ, Kimpton CP et al. A highly discriminating octoplex short tandem repeat polymerase chain reaction system suitable for human individual identification. Electrophoresis 1995; 16: 334-337.
25. Sharma V, Litt M. Tetranucleotide repeat polymorphism at the D21S11 locus. Hum Mol Genet 1992; 1: 67.
26. Urquhart A, Oldroyd NJ, Kimpton CP, Gill P. Highly discriminating heptaplex short tandem repeat PCR system for forensic identification. Biotechniques 1995; 18: 116-121.
27. Sullivan KM, Mannucci A, Kimpton CP, Gill P. A rapid and quantitative DNA sex test: fluorescence-based PCR analysis of X-Y homologous gene amelogenin. Biotechniques 1993; 15: 636-641.
28. Nagy M, Massenkeil G, Anders P et al. Short tandem repeat analysis to monitor chimerism after allogeneic stem cell transplantation. In: Sensabaugh GF, Lincoln PJ, Olaisen B (eds). Progress in Forensic Genetics 8: Proceedings of the 18th International ISFH Congress, San Francisco, CA, 1999, pp 561-563.
29. Sykes M, Preffer F, McAfee S et al. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet 1999; 353: 1755-1759.
30. Appelbaum FR. Allogeneic hematopoietic stem cell transplantation for acute leukemia. Semin Oncol 1997; 24: 114-123.
31. Matsue K, Tabayashi T, Yamada K, Takeuchi M. Eradication of residual bcr-abl-positive clones by inducing graft-versus-host disease after allogeneic stem cell transplantation in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Bone Marrow Transplant 2002; 29: 63-66.
32. Badros A, Barlogie B, Morris C et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood 2001; 97: 2574-2579.
33. De Lima M, Bonamino M, Vasconcelos Z et al. Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease. Bone Marrow Transplant 2001; 27: 73-78.
34. Ferra C, Rodriguez-Luaces M, Gallardo D et al. Individually adjusted prophylactic donor lymphocyte infusions after CD34-selected allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2001; 28: 963-968.
35. Sohn SK, Jung JT, Kim DH et al. Prophylactic growth factor-primed donor lymphocyte infusion using cells reserved at the time of transplantation after allogeneic peripheral blood stem cell transplantation in patients with high-risk hematologic malignancies. Cancer 2002; 94: 18-24.